Will Rousmaniere

Analogic Corp. engages in the business of designing, development manufacturing, and supporting technically advanced and cost-effective imaging and detection, and power and automation solutions for security, healthcare, and other high-end industrial markets. The firm is also involved in the innovation in the field of computed tomography. The company was founded by Bernard Marshall Gordon on November 27, 1967 and is headquartered in Peabody, MA.

Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.